JP4975947B2 - 健康飲料 - Google Patents
健康飲料 Download PDFInfo
- Publication number
- JP4975947B2 JP4975947B2 JP2003382398A JP2003382398A JP4975947B2 JP 4975947 B2 JP4975947 B2 JP 4975947B2 JP 2003382398 A JP2003382398 A JP 2003382398A JP 2003382398 A JP2003382398 A JP 2003382398A JP 4975947 B2 JP4975947 B2 JP 4975947B2
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- beverage
- test
- extract
- apple
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000036541 health Effects 0.000 title description 15
- 241000220225 Malus Species 0.000 claims description 31
- 229920001503 Glucan Polymers 0.000 claims description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 235000013361 beverage Nutrition 0.000 claims description 27
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 19
- 235000013824 polyphenols Nutrition 0.000 claims description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 13
- 229930003268 Vitamin C Natural products 0.000 claims description 13
- 235000019154 vitamin C Nutrition 0.000 claims description 13
- 239000011718 vitamin C Substances 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 12
- 241000223651 Aureobasidium Species 0.000 claims description 10
- 235000021016 apples Nutrition 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 239000000284 extract Substances 0.000 description 21
- 235000001727 glucose Nutrition 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000003266 anti-allergic effect Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000005760 tumorsuppression Effects 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 239000006173 Good's buffer Substances 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000002304 glucoses Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- -1 quercetin glycoside Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000222518 Agaricus Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229940068052 ginkgo biloba extract Drugs 0.000 description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 229930013783 (-)-epicatechin Natural products 0.000 description 1
- 235000007355 (-)-epicatechin Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102100034223 Golgi apparatus protein 1 Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000208251 Gymnema Species 0.000 description 1
- 240000007058 Halophila ovalis Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101001069963 Homo sapiens Golgi apparatus protein 1 Proteins 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000081841 Malus domestica Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 206010031256 Osteomyelitis chronic Diseases 0.000 description 1
- 235000016499 Oxalis corniculata Nutrition 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- NGSWKAQJJWESNS-UHFFFAOYSA-N cis-para-coumaric acid Natural products OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 235000020332 matcha tea Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- 229930188627 soysaponin Natural products 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
Description
(1)免疫増強作用:リンパ球の働きを強化し免疫機能を向上させる。
(2)抗腫瘍活性:ガン細胞がすでに発生し、発病してしまった後にそのガン細胞を攻撃する。
(3)ガン細胞増殖抑制作用:ガン細胞が発生した後、その増殖を抑え込む。
(4)抗アレルギー作用:アトピー性皮膚炎等のI型アレルギーを抑制する。
(5)抗炎症作用:免疫系の改善による防御機能を増進する。
(6)コレステロール低下作用:血中のコレステロールを低下させる。
(7)食物繊維効果:発ガン物質等を吸着して体外に排出する。
(8)抗血栓作用:血管内部が狭くなったり詰まったりすることを阻止する。
(9)血圧降下作用:心臓から送り出された血液が動脈壁に加える圧力によって異常をきたした時に正常な状態に戻す。
(10)血糖降下作用:血液中の過剰なブドウ糖を下げる。
(11)肝機能亢進:肝機能に対する解毒能力を向上させる。
β−1,3−1,6−グルカンを産生することは、Acta Chemical Scandinavia 17,
1351-1356(1963)(非特許文献1)、 Agric. Biol. Chem. 47(6),
1167-1172(1983)(非特許文献2)、 Chem. Pharm. Bull., 40,
2215(1992)(非特許文献3)等に記載されている通りである。
(1)アトピー性皮膚炎、花粉症、喘息等の各種アレルギー症状の低減効果。
(2)膠原病、リウマチ、HIV等の免疫異常疾患に対する改善効果。
(3)胃がん、肺がん、大腸がん、子宮がん、乳がん等各種のがんに対する抑制効果。
(4)心筋梗塞、脳梗塞等の血管障害疾患に対する改善効果。
(5)B型肝炎、C型肝炎等のウイルス性疾患に対する改善効果。
(6)糖尿病、排尿障害等の泌尿器系疾患に対する改善効果。
(7)便秘、下痢、口内炎、痔、食欲不振、二日酔い等の消化器系疾患の改善効果。
特開昭57−149301号公報に記載された方法に準じて、不完全菌黒色菌科アウレオバシジウム(Aureobacidium)属の微生物[微工研寄託番号4257号(FERM−P.4257)]を培養した。グルコースがβ−1,3グルコース結合した主鎖から非還元性末端がβ−1,6グルコース結合で分岐した構造を有し、リン酸基がグルコースに結合している高分子多糖を0.18重量%含有する培養液を得た。本培養液のpHは5.2であった。
・試料の調整法
上記実施例1の健康飲料を超音波破砕機(Ultrasonic Disruptor UR-200P)を用い、sonication処理(200W/20min.)後、超遠心操作(35000rpm/30min.)により上清を得、これをHEPES
Good buffer(ph7.4, μ0.15)にて10倍希釈したものを被験材料とした。
また、比較試料としてアガリクス茸の子実体を乾燥した粉末を10%(w/v)濃度となるようHEPES
Good buffer(ph7.4, μ0.15)に懸濁し、更に超音波破砕機(Ultrasonic Disruptor UR-200P)を用い、sonication処理(200W/10min.)後、2時間熱水抽出操作を行った。その後、超遠心操作(35000rpm/30min.)により上清を得、これを出発材料重量より換算して1%(w/v)濃度になるようにHEPES Good buffer(ph7.4, μ0.15)にて希釈して被験材料とした。
(1)実験動物:
BALB/cマウス(雌、6週齢)を1群5匹の系で使用した。
(2)Sarcoma180固形癌のマウスへの移植:
Sarcoma(肉腫)180細胞株を37C/5%CO2インキュベータ中、10%FCS/RPMI-1640培養液にて継代培養した。対数増殖期(Full seat)にある同細胞をTrypsin-EDTAにより培養フラスクより剥離した後、RPMI‐1640培養液で洗浄し、細胞数を 5,000,000cells/mLとなるように調整したものを使用した。この0.1mlをそれぞれの被験マウス背部皮下に移植した。操作はすべて無菌的に行なった。
(3)抽出成分の投与方法
マウスにSarcoma180固形癌細胞を移植した24時間後より、0.22μmフィルターにて無菌ろ過した前記被験材料を、1日1回(0.1ml)ずつ、それぞれ14日間、腹腔内(ip)投与した。
腫瘍細胞移植3週間後にマウスを屠殺し、移植後生着腫瘍重量(g)を測定し、対照群(control)と比較して腫瘍抑制率(%)を算出した結果を表1に示す。
ここでの対象群は、前記被験材料の代わりにNa-Phosphate Buffered Saline(PBS)を投与したものである。
・細胞の調製
下記(1)〜(6)の各細胞株を37C/5%CO2インキュベータ中で、10%FCSを含むRPMI1640培養液環境下、25cm2培養フラスク内で浮遊増殖培養を行った。各細胞とも対数増殖期にある時点でRPMI1640培養液環境下に洗浄置換して、細胞数が400,000-800,000cells/mLとなるように調整した。
Acute lymphoblastic leukemia - T lymphocyte(Human - lympoblast)
(急性リンパ性白血病)
(2)K562細胞:
Chronic myelogenous leukemia - bone marrow(Human - lymphoblast)
(慢性骨髄炎)
(3)MOLT-4CL#8細胞:
Acute lymphoblastic leukemia - T lymphoblast(Human - lymphoblast)
(急性リンパ性白血病)
(4)U937細胞:
Histiocytic lymphoma - macrophage, histiocyte(Human - monocyte)
(組織リンパ腫)
(5)Raji細胞:
Burkitt lymphoma - EBV infected B lymphocyte(Human - lymphoblast)
(バーキットリンパ腫)
(6)YAC-1細胞:
Natural killer cell - sensitive lymphoma(Mouse - lymphoblast)
(NK細胞)
前記マウスによる抗腫瘍実験で用いた本願実施例1の健康飲料から得られた被験材料を出発材料として、10倍希釈溶液(原液の1%溶液)、20倍、100倍希釈溶液となるようにNa-Phosphate Buffered Saline(PBS)で希釈したものを作成し、これを0.22μmフィルターにて無菌ろ過し、被験材料とした。
更に、上記(1)〜(6)の調製培養細胞浮遊液をそれぞれ96well cell culture plate中に100μリットルずつ分注し、この中に被験材料を等量添加し、よく混和した後、再び37C/5%CO2インキュベータ中で36時間反応培養を行った。
次に、これらの各培養細胞を0.5%Trypan blueにて染色し、反応後の生細胞の数を計測し、Control(PBS)と比較することで各腫瘍細胞に対する抗腫瘍(増殖抑制)活性として算出した。
各腫瘍細胞に対して、各濃度の被験材料ごとの生細胞数及び生細胞比を、対照(Control)と比較した結果を表2に示す。結果から明らかなように、本発明に係る健康食品は、血液腫瘍細胞に対する抗腫瘍効果を有している。
・被験飼料
実施例1で得られた健康飲料の、ヒトの1日あたりの摂取量(60kgの体重で40ml)に相当する量を、ヒトとマウス(約20g)の体重比から算出した。この算出量の約25〜30倍の量が摂取濃度(経口投与実験設定濃度)となるように、通常のマウス飼育用紛餌の中に均等に混合した後、固形型打ち及び放射線滅菌して、被験飼料として用いた。マウス飼料中の実質濃度は約5%である。対照(control)群は通常のマウス滅菌固形飼料のみを摂取した。
アトピー性皮膚炎自然発症マウス(NC/Nga mouse, clean, CV;生後4週齢のものを日本SLC株式会社より入手)を用い、雌雄それぞれ1群10匹の系で行い、上記の被験飼料投与群及び対照群の、計4群にて行った。
上記実験動物はすべて入荷後1週間の予備飼育をした後、第5週齢より第16種齢に至るまでの間を観察期間とした。
飼育条件は24±1℃、相対湿度55±5%、明暗各12時間(照明時間:午前7時〜午後7時)ヘパフィルターにより除菌された新鮮空気による換気回数を1時間当たり12回以上に設定されたバリアシステム動物飼育室(マウス、ラット室)で飼育した。飼育には滅菌床敷を入れた滅菌済みのプラスチック製ケージを用いて、4〜6匹飼いで飼育した。ケージの交換は週1回とし、飼料は固形飼料(オリエンタル酵母社製、CFR-1)を給餌器に入れ、飲料水は水道水を滅菌給水瓶に入れてそれぞれ自由に摂取させ飼育した。
また、投与11週後(16週齢)における肉眼的皮膚所見について比較観察した。
雄及び雌のマウスの、血中IgE濃度の加齢による変動について表3に示す。血中IgE濃度の総量は、固体の発育とともに上昇傾向が認められたが、上記被験飼料摂取群においては、対照群とを比較して優位に血中IgE産生の抑制が認められる結果が得られた。特に、投与11週後(16週齢)における血中IgE値では、雌雄の両群において統計学的にt検定を行ったところ、危険率p<0.05上での有意な差異が認められた。
・検体
検体1;
実施例1と同様に培養されたアウレオバシジウム培養液にニッカウヰスキー株式会社製「アップルフェノン(登録商標)」を0.1重量%配合したもの
検体2;
実施例1と同様に培養されたアウレオバシジウム培養液のみ
試験菌1;
Staphylococcus aureus IFO 12732
試験菌2;
Klebsiella pneumoniae IFO 13277
検体1及び2各10mlに、上記試験菌1及び2の菌液をそれぞれ100,000個/ml程度になるように添加して35℃で保存し、開始時、保存開始6時間後及び24時間後に試験液中の生菌数を測定した。また、対照として菌液のみを同様に保存して生菌数を測定した。
試験結果を表4にまとめて示す。
表から明らかなように、β−1,3−1,6−グルカンを含有する検体1、2ともに抗菌力を示しており、いずれの試験菌に対しても抗菌効果を有することがわかる。しかも、更にリンゴ抽出物を含有する含有する検体1の方がより強い抗菌力を有することが、6時間後の段階での生菌数から明確である。
Claims (3)
- β−1,3−1,6−グルカンを生合成するアウレオバシジウム属の微生物の培養液及びリンゴから抽出されたポリフェノールを含有する飲料。
- リンゴから抽出されたポリフェノールが、リンゴの未熟果から抽出されたものである請求項1に記載の飲料。
- 更にビタミンCを配合してpHを4〜6に調整してなる請求項1又は2に記載の飲料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003382398A JP4975947B2 (ja) | 2003-11-12 | 2003-11-12 | 健康飲料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003382398A JP4975947B2 (ja) | 2003-11-12 | 2003-11-12 | 健康飲料 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001143895A Division JP3523220B2 (ja) | 2001-05-14 | 2001-05-14 | 皮膚塗布剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004075692A JP2004075692A (ja) | 2004-03-11 |
JP4975947B2 true JP4975947B2 (ja) | 2012-07-11 |
Family
ID=32025947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003382398A Expired - Lifetime JP4975947B2 (ja) | 2003-11-12 | 2003-11-12 | 健康飲料 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4975947B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190032183A (ko) * | 2017-09-19 | 2019-03-27 | (주)큐젠바이오텍 | 베타글루칸을 유효성분으로 하는 숙취 해소용 조성물 또는 알코올성 간질환 예방, 개선 또는 치료용 조성물 |
WO2019059549A3 (ko) * | 2017-09-19 | 2019-05-09 | 주식회사 큐젠바이오텍 | 베타글루칸을 유효성분으로 하는 숙취 해소용 조성물 또는 알코올성 간질환 예방, 개선 또는 치료용 조성물 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004027120D1 (de) * | 2004-05-25 | 2010-06-24 | Cognis Ip Man Gmbh | Orale und/oder topische Zubereitungen |
JP5072286B2 (ja) * | 2006-08-25 | 2012-11-14 | 株式会社林原 | 動物の免疫調節剤 |
CN103704836A (zh) * | 2013-12-19 | 2014-04-09 | 芜湖佳诚电子科技有限公司 | 一种茶香木耳饮料及其制备方法 |
JP5717224B1 (ja) * | 2014-08-28 | 2015-05-13 | 株式会社ビオコスモ | 粉末状の機能性食品及びその製造方法 |
TWI804469B (zh) * | 2016-07-01 | 2023-06-11 | 美商阿爾塞斯商業集團國際有限公司 | 用於重量管理之以植物為基礎的組成物及使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3521155B2 (ja) * | 1993-12-06 | 2004-04-19 | ニッカウヰスキー株式会社 | 果実ポリフェノールの製造方法 |
JP3957087B2 (ja) * | 1995-05-29 | 2007-08-08 | ニッカウヰスキー株式会社 | リンゴ赤色色素とその製造方法、酸化防止剤、血圧降下剤、アレルギー抑制剤、抗う蝕剤及び消臭剤 |
JPH10276740A (ja) * | 1997-04-09 | 1998-10-20 | Hiroshi Hattori | β−1,3−1,6グルカンを含む飲食物の製法 |
-
2003
- 2003-11-12 JP JP2003382398A patent/JP4975947B2/ja not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190032183A (ko) * | 2017-09-19 | 2019-03-27 | (주)큐젠바이오텍 | 베타글루칸을 유효성분으로 하는 숙취 해소용 조성물 또는 알코올성 간질환 예방, 개선 또는 치료용 조성물 |
WO2019059549A3 (ko) * | 2017-09-19 | 2019-05-09 | 주식회사 큐젠바이오텍 | 베타글루칸을 유효성분으로 하는 숙취 해소용 조성물 또는 알코올성 간질환 예방, 개선 또는 치료용 조성물 |
KR102118731B1 (ko) * | 2017-09-19 | 2020-06-03 | (주)큐젠바이오텍 | 베타글루칸을 유효성분으로 하는 숙취 해소용 조성물 또는 알코올성 간질환 예방, 개선 또는 치료용 조성물 |
US11154568B2 (en) | 2017-09-19 | 2021-10-26 | Quegen Biotech Co., Ltd. | Composition for relieving hangover or composition for preventing, alleviating or treating alcoholic liver disease, comprising b-glucan as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
JP2004075692A (ja) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5306537B2 (ja) | 昆布抽出物を有効成分とする抗菌補助剤、抗菌組成物、及び飲食品 | |
JP6086568B2 (ja) | 食品添加剤及び食品 | |
EP1390071A2 (de) | Symbiontisches regenerativum | |
CA2878005A1 (en) | Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodetes to microbiota of firmicutes phylum | |
EP3141254B1 (en) | Lactobacillus rhamnosus rht-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
EP1965809A2 (en) | Novel compositions to improve gut health and animal performance and methods of making the same | |
JP2012019764A (ja) | 飲料 | |
KR101614574B1 (ko) | 탱자 발효물에 의한 비만개선효과물질의 조성 | |
JP4975947B2 (ja) | 健康飲料 | |
JP4205334B2 (ja) | 茶に由来する薬理組成物 | |
KR102104838B1 (ko) | 크로톤 포일라네이 추출물을 이용한 항진균용 조성물 | |
KR101461165B1 (ko) | 숙취해소용 식품조성물 | |
JP3523220B2 (ja) | 皮膚塗布剤 | |
KR101472190B1 (ko) | 식물성 유산균 락토바실러스 플란타룸 피엠오08 사균체를 유효성분으로 포함하는 변비 예방, 치료 또는 개선용 조성물 | |
WO2007135766A1 (ja) | 口腔内腫瘍改善又は治療用軟膏剤 | |
JP3829107B2 (ja) | 免疫反応性NO合成を誘導するiNOS酵素を刺激する組成剤およびその製造方法 | |
RU2437582C1 (ru) | Способ увеличения сроков хранения соков, цельного молока, жидких молочных и других жидких пищевых продуктов с помощью механохимического биопрепарата наноягель-м | |
JP5320965B2 (ja) | β−1,3−1,6−D−グルカンを用いた消化管粘膜保護剤または下痢抑制剤 | |
KR101898891B1 (ko) | 진세노사이드 화합물 k를 이용한 세포독성 항암제 부작용 억제용 조성물 | |
JP6194192B2 (ja) | アディポネクチン産生促進剤 | |
KR20230052922A (ko) | 면역 증강 및 호흡기 건강을 위한 상승적인 허브 조성물 | |
JP2009234984A (ja) | 腎機能の低下抑制または改善剤 | |
JP6629469B1 (ja) | コンドロイチン硫酸含有ブタ軟骨抽出物を有効成分とする血圧上昇抑制剤およびそれを含有する食品組成物 | |
US8124137B2 (en) | Composition for prevention and/or treatment of tumors containing acacia bark derivative | |
KR101978819B1 (ko) | 진세노사이드 화합물 k를 이용한 지방성 간질환 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110809 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120412 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4975947 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150420 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |